Treatment of oesophageal bile reflux in children: The results of a prospective study with omeprazole

Journal of Pediatric Gastroenterology and Nutrition

Volumn 42, Issue 4, 2006, Pages 376-383

  Orel, Rok ^a,c   Brecelj, Jernej ^a   Homan, Matjaž ^a   Heuschkel, Robert ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c Pediatricna Klinika Ljubljana   (Slovenia)

Author keywords

Children; DGOR duodenogastro oesophageal reflux; Omeprazole; Therapy

Indexed keywords

BILE ACID; OMEPRAZOLE; PROTON PUMP INHIBITOR; SCOPOLAMINE; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BILE REFLUX; BODY POSTURE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; COMMON BILE DUCT STONE; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG CAPSULE; DUODENOGASTROESOPHAGEAL REFLUX; ENDOSCOPIC PAPILLOTOMY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ESOPHAGITIS; FEVER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HIATUS HERNIA; HUMAN; MUSCULOSKELETAL PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETT SYNDROME; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ANTI-ULCER AGENTS; BILE REFLUX; CHILD; CHILD, PRESCHOOL; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MUCOUS MEMBRANE; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33744937317     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000214162.45198.0f     Document Type: Article

References (45)

1. Richter JE. Duodenogastric reflux-induced (alkaline) esophagitis. Curr Treat Options Gastroenterol 2004;7(1):53-8.
2. Dixon MF, Mapstone NP, Neville PM, et al. Bile reflux and intestinal metaplasia at the cardia. Gut 2002;51(3):351-5.
3. Galli J, Cammarota G, Calo L, et al. The role of acid and alkaline reflux in laryngeal squamous cell carcinoma. Laryngoscope 2002;112(10):1861-5.
4. Galli J, Calo L, Agostino S, et al. Bile reflux as possible risk factor in laryngopharyngeal inflammatory and neoplastic lesions. Acta Otorhinolaryngol Ital 2003;23(5):377-82.
5. Szentpali K, Eros G, Kaszaki J, et al. Microcirculatory changes in the canine oesophageal mucosa during experimental reflux esophagitis: comparison of the effects of acid and bile. Scand J Gastroenterol 2003;38(10):1016-22.
6. Jang TJ, Min SK, Bea JD, et al. Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett's metaplasia induced by duodenal contents reflux. Gut 2004;53(1):27-33.
7. 2 via bile acid is enhanced by trypsin and acid in normal human esophageal epithelial cells. Life Sci 2004;75(1):21-34.
8. Sung MW, Roh JL, Park BJ, et al. Bile acid induces cyclooxygenase-2 expression in cultured human pharyngeal cells: a possible mechanism of carcinogenesis in the upper aerodigestive tract by laryngopharyngeal reflux. Laryngoscope 2003;113(6):1059-63.
9. Orel R, Markovic S. Bile in esophagus: a factor in the pathogenesis of reflux esophagitis in children. J Pediatr Gastroenterol Nutr 2003;36:266-73.
10. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 2000;137:800-7.
11. Pashankar D, Blair G, Israel D. Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication. J Pediatr Gastroenterol Nutr 2001;32:145-9.
12. Gunasekaran T, Gupta D, Gremse D, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, symptom relief efficacy, and tolerability. J Pediatr Gastroenterol Nutr 2002;35:S327-35.
13. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002;35:S308-18.
14. Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002;35:S300-7.
15. Colletti RB, Di Lorenzo C. Overview of pediatric gastroesophageal reflux disease and proton pump inhibitor therapy. J Pediatr Gastroenterol Nutr 2003;37:S7-11.
16. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994;107:747-54.
17. Marshall RE, Anggiansah A, Manifold DK, et al. Effect of omeprazole 20 mg twice daily on duodenogastric and gastrooesophageal bile reflux in Barrett's esophagus. Gut 1998;43:603-6.
18. Menges M, Muller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol 2001:331-7.
19. Lundell LR, Dent J, Bennet JR, et al. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80.
20. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192-9.
21. Hassall E. Macroscopic versus microscopic diagnosis of reflux esophagitis: erosions or eosinophils? J Pediatr Gastroenterol Nutr 1996;22:321-5.
22. Bechi P, Pucciani F, Baldini S, et al. Long-term ambulatory enterogastric reflux monitoring. Dig Dis Sci 1993;38:1297-306.
23. Kauer WKH, Burdiles P, Ireland AP, et al. Does duodenal juice reflux into the esophagus of patients with complicated GERD? Evaluation of a fiberoptic sensor for bilirubin. Am J Surg 1995;169:98-104.
24. Johnson LF, DeMeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974;62:325-32.
25. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology 1992;102(1):109-18.
26. Earnest DL, Dorsch E, Jones J, et al. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998;93(2):238-43.
27. Sasaki CT, Marotta J, Hundal J, et al. Bile-induced laryngitis: is there a basis in evidence? Ann Otol Rhinol Laryngol 2005;114(3):192-7.
28. Bollschweiler E, Wolfgarten E, Putz B, et al. Bile reflux into the stomach and the esophagus for volunteers older than 40 years. Digestion 2005;71(2):65-71.
29. Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004;99(6):981-8.
30. Sarela AI, Hick DG, Verbeke CS, et al. Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. Arch Surg 2004;139(5):547-551.
31. Cuomo R, Koek G, Sifrim D, et al. Analysis of ambulatory duodenogastroesophageal reflux monitoring. Dig Dis Sci 2000; 45(12):2463-9.
32. Wenzl TG, Moroder C, Trachterna M, et al. Esophageal pH monitoring and impedance measurement: a comparison of two diagnostic tests for gastroesophageal reflux. J Pediatr Gastroenterol Nutr 2002;34(5):519-23.
33. Raufman JP, Cheng K, Zimniak P. Activation of muscarinic receptor signaling by bile acids: physiological and medical implications. Dig Dis Sci 2003;48(8):1431-44.
34. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;21(284 (5418)):1365-8.
35. Beuers U, Throckmorton DC, Anderson MS, et al. Taurourso-deoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology 1996;110(5):1553-63.
36. Jenkins GJ, Harries K, Doak SH, et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004;25(3):317-23.
37. Theisen J, Peters JH, Fein M, et al. The mutagenic potential of duodenoesophageal reflux. Ann Surg 2005;241(1):63-8.
38. Vaezi MF, Sears R, Richter JE. Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. Dig Dis Sci 1996;41(4):754-63.
39. Hermans D, Sokal EM, Collard JM, et al. Primary duodenogastric reflux in children and adolescents. Eur J Pediatr 2003;162(9):598-602.
40. Lehmann A, Antonsson M, Bremner-Danielsen M, et al. Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999;117(5):1147-54.
41. Vela MF, Tutuian R, Katz PO, et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003;17(2):243-51.
42. Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003;52(10):1397-402.
43. Fountos A, Chrysos E, Tsiaoussis J, et al. Duodenogastric reflux after biliary surgery: scintigraphic quantification and improvement with erythromycin. ANZ J Surg 2003;73(6):400-3.
44. Stein HJ, Kauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and Nissen fundoplication. J Gastrointest Surg 1998;2(4):333-41.
45. Klingler PJ, Perdikis G, Wilson P, et al. Indications, technical modalities and results of the duodenal switch operation for pathologic duodenogastric reflux. Hepatogastroenterology 1999;46(25):97-102.